1. A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
- Author
-
Kim, Woohyeun, Chang, Kiyuk, Cho, Eun Joo, Ahn, Jeong‐Cheon, Yu, Cheol Woong, Cho, Kyoung‐Im, Kim, Yong‐Jin, Kang, Duk‐Hyun, Kim, Seok‐Yeon, Lee, Sang‐Hak, Kim, Ung, Kim, Shin‐Jae, Ahn, Young Keun, Lee, Chang Hoon, Shin, Jin Ho, Kim, Mikyung, Park, Chang Gyu, Ahn, Jeong-Cheon, Cho, Kyoung-Im, and Kim, Yong-Jin
- Subjects
DRUG therapy for hyperlipidemia ,HYPERTENSION ,ANTIHYPERTENSIVE agents ,BLOOD pressure ,RESEARCH ,COMBINATION drug therapy ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,HYPERLIPIDEMIA ,TREATMENT effectiveness ,COMPARATIVE studies ,RANDOMIZED controlled trials ,BLIND experiment ,RESEARCH funding ,AMLODIPINE - Abstract
This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia. A total of 106 patients of 15 institutions in Korea were randomly assigned to 1 of 3 treatment groups: rosuvastatin 20 mg + amlodipine 10 mg, amlodipine 10 mg, or rosuvastatin 20 mg. After 8 weeks of treatment, the mean ± SD of change in mean sitting systolic blood pressure (msSBP) was -22.82 ± 12.99 mm Hg in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. The percentage of patients whose msSBP decreased ≥20 mm Hg or msDBP decreased ≥10 mm Hg was also highest in this group (74.29%). The mean ± SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% ± 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). No serious adverse events or adverse drug reactions were observed in all groups. In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF